Last reviewed · How we verify
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
Details
| Lead sponsor | Enzymotec |
|---|---|
| Phase | NA |
| Status | TERMINATED |
| Enrolment | 97 |
| Start date | 2014-09 |
| Completion | 2017-12-25 |
Conditions
- Mild Cognitive Impairment
Interventions
- Phosphatidylserine
- Placebo
Primary outcomes
- Difference in change in the Selective Reminding Test (SRT) between the study groups. — baseline, 3, 6,12 months
Countries
United States, Israel